These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 24700557)

  • 1. Minimizing signal detection time in postmarket sequential analysis: balancing positive predictive value and sensitivity.
    Maro JC; Brown JS; Dal Pan GJ; Kulldorff M
    Pharmacoepidemiol Drug Saf; 2014 Aug; 23(8):839-48. PubMed ID: 24700557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of exposure accrual on sequential postmarket evaluations: a simulation study.
    Maro JC; Brown JS
    Pharmacoepidemiol Drug Saf; 2011 Nov; 20(11):1184-91. PubMed ID: 22020903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medical product safety surveillance: how many databases to use?
    Maro JC; Brown JS; Kulldorff M
    Epidemiology; 2013 Sep; 24(5):692-9. PubMed ID: 23867812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges in the design and analysis of sequentially monitored postmarket safety surveillance evaluations using electronic observational health care data.
    Nelson JC; Cook AJ; Yu O; Dominguez C; Zhao S; Greene SK; Fireman BH; Jacobsen SJ; Weintraub ES; Jackson LA
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():62-71. PubMed ID: 22262594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative performance of two quantitative safety signalling methods: implications for use in a pharmacovigilance department.
    Almenoff JS; LaCroix KK; Yuen NA; Fram D; DuMouchel W
    Drug Saf; 2006; 29(10):875-87. PubMed ID: 16970511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of Interoperable Computable Phenotype Algorithms for Adverse Events of Special Interest to Be Used for Biologics Safety Surveillance: Validation Study.
    Holdefer AA; Pizarro J; Saunders-Hastings P; Beers J; Sang A; Hettinger AZ; Blumenthal J; Martinez E; Jones LD; Deady M; Ezzeldin H; Anderson SA
    JMIR Public Health Surveill; 2024 Jul; 10():e49811. PubMed ID: 39008361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system.
    Harpaz R; DuMouchel W; LePendu P; Bauer-Mehren A; Ryan P; Shah NH
    Clin Pharmacol Ther; 2013 Jun; 93(6):539-46. PubMed ID: 23571771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Towards Automating Adverse Event Review: A Prediction Model for Case Report Utility.
    Muñoz MA; Dal Pan GJ; Wei YJ; Delcher C; Xiao H; Kortepeter CM; Winterstein AG
    Drug Saf; 2020 Apr; 43(4):329-338. PubMed ID: 31912439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An evaluation of computer-aided disproportionality analysis for post-marketing signal detection.
    Lehman HP; Chen J; Gould AL; Kassekert R; Beninger PR; Carney R; Goldberg M; Goss MA; Kidos K; Sharrar RG; Shields K; Sweet A; Wiholm BE; Honig PK
    Clin Pharmacol Ther; 2007 Aug; 82(2):173-80. PubMed ID: 17507922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A conditional maximized sequential probability ratio test for pharmacovigilance.
    Li L; Kulldorff M
    Stat Med; 2010 Jan; 29(2):284-95. PubMed ID: 19941282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical device active surveillance of spontaneous reports: A literature review of signal detection methods.
    Chung G; Etter K; Yoo A
    Pharmacoepidemiol Drug Saf; 2020 Apr; 29(4):369-379. PubMed ID: 32128936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do delays in data availability limit the implementation of near real-time vaccine safety surveillance using the Clinical Practice Research Datalink?
    Leite A; Thomas SL; Andrews NJ
    Pharmacoepidemiol Drug Saf; 2018 Jan; 27(1):25-29. PubMed ID: 29193554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postmarketing surveillance of potentially fatal reactions to oncology drugs: potential utility of two signal-detection algorithms.
    Hauben M; Reich L; Chung S
    Eur J Clin Pharmacol; 2004 Dec; 60(10):747-50. PubMed ID: 15619136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A reference standard for evaluation of methods for drug safety signal detection using electronic healthcare record databases.
    Coloma PM; Avillach P; Salvo F; Schuemie MJ; Ferrajolo C; Pariente A; Fourrier-Réglat A; Molokhia M; Patadia V; van der Lei J; Sturkenboom M; Trifirò G
    Drug Saf; 2013 Jan; 36(1):13-23. PubMed ID: 23315292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Signal detection using change point analysis in postmarket surveillance.
    Xu Z; Kass-Hout T; Anderson-Smits C; Gray G
    Pharmacoepidemiol Drug Saf; 2015 Jun; 24(6):663-8. PubMed ID: 25903221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simulation study comparing exposure matching with regression adjustment in an observational safety setting with group sequential monitoring.
    Stratton KG; Cook AJ; Jackson LA; Nelson JC
    Stat Med; 2015 Mar; 34(7):1117-33. PubMed ID: 25510526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Food and Drug Administration's Post-Licensure Rapid Immunization Safety Monitoring program: strengthening the federal vaccine safety enterprise.
    Nguyen M; Ball R; Midthun K; Lieu TA
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():291-7. PubMed ID: 22262619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of statistical signal detection procedures in eudravigilance post-authorization data: a retrospective evaluation of the potential for earlier signalling.
    Alvarez Y; Hidalgo A; Maignen F; Slattery J
    Drug Saf; 2010 Jun; 33(6):475-87. PubMed ID: 20486730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statistical visualization for assessing performance of methods for safety surveillance using electronic databases.
    Li X; Hui S; Ryan P; Rosenman M; Overhage M
    Pharmacoepidemiol Drug Saf; 2013 May; 22(5):503-9. PubMed ID: 23408560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The US Food and Drug Administration's Sentinel Initiative: expanding the horizons of medical product safety.
    Robb MA; Racoosin JA; Sherman RE; Gross TP; Ball R; Reichman ME; Midthun K; Woodcock J
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():9-11. PubMed ID: 22262587
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.